Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523117 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL8445624 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL1148693 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL1148775 | 1.00 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 | |
| Water SCHEMBL27660893 | 0.98 | IDO1 (0.41) | IDO1PDPK1MAOAMAOBCA1 | |
| SCHEMBL29795931 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL1148722 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL3318970 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL28568250 | 0.82 | ALDH1A1 (0.34) | — | |
| SCHEMBL2541173 | 0.81 | IDO1 (0.42) | IDO1PDPK1MAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0711272-A1 | INDANE AND TETRAHYDRONAPHTHALENE DERIVATIVES AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004028-A1 | INDANE AND TETRAHYDRONAPHTHALENE DERIVATIVES AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | IDO1 396/4885PDPK1 425/4885MAOA 4106/4885 |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | IDO1 3119/4885PDPK1 3494/4885MAOA 4852/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | IDO1 396/4885PDPK1 425/4885MAOA 4106/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | IDO1 158/4885PDPK1 312/4885MAOA 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.